A Retrospective Study in Patients With Mild to Moderate COVID-19
A Retrospective, Real World Study to Analyze Disease Outcomes in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This study is a retrospective, real world study, without any intervention in clinical diagnosis and treatment, and only real world data are collected for analysis.
The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.
The study will collect and analyze available symptoms, risk factors and SARS-COV-2 Ct value up to 28 days.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Minghua Yu
- Phone Number: +86-18017821601
- Email: minghua_md@fudan.edu.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Shanghai Pudong Hospital
-
Contact:
- Minghua Yu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants who have a positive SARS-CoV-2 test result.
- Participants who have one or more mild or moderate COVID-19 symptoms.
- Participants who have one or more of the following requirements: ≤7 days from the first positive test for SARS-COV-2 virus infection to Day 1; ≤5 days from the first onset of COVID-19 symptoms to Day 1.
- Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death.
Exclusion Criteria:
- Participants who are diagnosed with severe/critical COVID-19 before Day 1.
- Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute before Day 1.
- Participants who have received mechanical ventilation before Day 1.
- Participants who have received or plan to receive a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) before and during hospitalization.
- Participants who have received convalescent COVID-19 plasma treatment before and during hospitalization.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patient with COVID-19
Mild to moderate COVID-19 patient with at least one risk factor for serve COVID-19 illness or death.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of the participants who have progression of COVID-19
Time Frame: Day 1 to 28 days
|
Percentage of participants who experience these events: Progress to severe and/or critical COVID-19; Death from any cause
|
Day 1 to 28 days
|
|
Percentage of participants who experience these events
Time Frame: Day 1 to 28 days
|
Percentage of participants who experience these events: Progress to severe and/or critical COVID-19; Death from any cause
|
Day 1 to 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to sustained clinical recovery
Time Frame: Up to 28 days
|
Time to sustained clinical recovery
|
Up to 28 days
|
|
Time to sustained disappearance of clinical symptoms
Time Frame: Up to 28 days
|
Time to sustained disappearance of clinical symptoms
|
Up to 28 days
|
|
Time to initial negative conversion of SARS-COV-2
Time Frame: Up to 28 days
|
Time to initial negative conversion of SARS-COV-2
|
Up to 28 days
|
|
Time to sustained negative conversion of SARS-CoV-2
Time Frame: Up to 28 days
|
Time to sustained negative conversion of SARS-CoV-2
|
Up to 28 days
|
|
Percentage of participants who turned negative for SARS-CoV-2
Time Frame: Day 3, 5, 7, 10, 14
|
Percentage of participants who turned negative for SARS-COV-2 at Day 3, 5, 7, 10, 14
|
Day 3, 5, 7, 10, 14
|
|
The change of SARS-COV-2 Ct value
Time Frame: Day 3, 5, 7, 10, 14
|
The change of SARS-COV-2 Ct value The change of SARS-COV-2 Ct value at Day 3, 5, 7, 10, 14
|
Day 3, 5, 7, 10, 14
|
|
Safety assessment Results: such as AEs and SAEs through Day 28
Time Frame: Up to 28 days
|
Safety assessment Results: such as AEs and SAEs through Day 28
|
Up to 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Minghua Yu, Shanghai Pudong Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- JT001-011-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.